Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

REC-4881 · TAK-733

Small molecule · Inhibitor of MEK1 (MAP2K1) (MAP2K1) and MEK2 (MAP2K2) (MAP2K2) · developed by Recursion Pharmaceuticals

Phase 1/2 Most advanced trial
RXRX Developer
1 Registered trials

What is REC-4881?

REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small-molecule inhibitor of MEK1 and MEK2 kinases. It binds these enzymes to block activation of the RAS/RAF/MEK/ERK pathway and tumor cell proliferation. It is being studied in familial adenomatous polyposis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TAK-733
Drug type
Small molecule
Targets
MEK1 (MAP2K1) (MAP2K1), MEK2 (MAP2K2) (MAP2K2)
Mechanism
Inhibitor of MEK1 (MAP2K1) (MAP2K1) and MEK2 (MAP2K2) (MAP2K2)
Pathways
RAS/RAF/MEK/ERK pathway, growth factor-mediated cell signaling
Therapy area
Oncology
Developer
Recursion Pharmaceuticals Inc. (RXRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
5J61HSP0QJ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05552755 Phase 1/2 Familial Adenomatous Polyposis Recruiting RXRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Familial Adenomatous Polyposis

Other drugs acting on MAP2K1 / MAP2K2

More from Recursion Pharmaceuticals

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RXRX page.

Follow RXRX, the company behind REC-4881

See RXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RXRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.